Humacyte's book value per share represents the net asset value of the enterprise calculated from its latest balance sheet data, dividing total shareholders' equity by outstanding shares. Because clinical-stage biotechnology firms regularly expend capital on research, development, and manufacturing scale-ups without realizing massive immediate revenues, book values fluctuate dynamically following periodic equity offerings, warrant conversions, and operating expense burn rates.